Isis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Xing-Xian Yu

Sanjay Bhanot

Brett P Monia

Kenneth W Dobie

Susan M Freier

Robert McKay

Ravi Jain

Sanjay K Pandey

Michael L Mccaleb

Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 4 are provided.

Antisense modulation of fibroblast growth factor receptor 4 expression

Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.

Modulation of diacylglycerol acyltransferase 2 expression

Methods are provided for modulating RBP4 by administering a RBP4-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the modulation of RBP4. The present invention is also directed to methods of decreasing lipid levels in a subject or for preventing or delaying the onset of a rise in lipid levels in a subject, comprising administering to said subject a RBP4-specific inhibitor.

Methods for modulating expression of RBP4

Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.

Compositions and their uses directed to diacylglycerol acyltransferase 1

The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.

Compositions and methods for the modulation of JNK proteins

Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 2 are provided.

Growing community of inventors

San Diego, CA, United States of America

Xing-Xian Yu